Bengaluru-based Peptris Technologies has signed an agreement for Rs 86 crore in support from the Technology Development Board under the Research Development and Innovation Fund. Announced on 12 October, the financing will support a three-year programme to move four AI-discovered drug candidates through further development and towards clinical work.
The support will take the form of optionally convertible debt. It is not described as a grant or a completed equity funding round. The project's total cost is Rs 172 crore, so the announced RDI support accounts for half of that amount. The release does not say the full support has already been disbursed.
The programme is called VIGOR: Advancing AI-Discovered Molecules from Bench to Clinic. According to the TDB-DST agreement announcement, all four candidates are at Technology Readiness Level 4, with the project aiming to take them to Level 6. These are development targets rather than a declaration that a medicine is ready for patients.
The choice of instrument also limits what can be concluded about ownership. An optionally convertible debt agreement is not evidence that an investor has already acquired a particular shareholding. The release gives no valuation or conversion ratio, so neither can be inferred from the Rs 86 crore figure.
Four candidates, a three-year development plan
The candidates cover different research areas. PEPR111 targets neuromuscular disorders and oncology, while PEPRX101 is being developed for alopecia. PEPR202 targets neuropathy and PEPR112 focuses on DMD. The announcement identifies them as drug candidates, with scientific and regulatory work still ahead.
The planned work includes advanced preclinical studies and studies intended to support investigational new drug applications. Formulation development, preparation for clinical trials and trial-initiation activities are also included, subject to the relevant requirements. The release does not provide individual trial dates, trial locations or patient-enrolment details.
Peptris will combine its proprietary AI discovery platform with experimental validation and conventional drug-development work. The programme also envisages using global contract research organisation networks for development and validation. Computer-led identification is therefore one part of the proposed workflow, followed by work needed to examine how the candidates behave in testing.
The distinction matters when reading an AI drug-discovery announcement. A computational result can help select a candidate for further investigation, but the financing announcement contains no clinical outcome data establishing safety or effectiveness. Neither the use of AI nor public financial support can substitute for that evidence.
How the support fits the RDI structure
The RDI Fund's published financing mechanism uses two levels. A special purpose fund under the Anusandhan National Research Foundation holds the scheme's resources, while approved second-level institutions implement financing. The scheme lists long-term loans, equity financing in selected cases and contributions to deep-tech funds of funds. The instrument specified for this Peptris agreement is optionally convertible debt.
The scheme's official overview includes biotechnology, pharmaceuticals and medical devices among its priority areas, as well as AI applications in health. It supports research-intensive technology development at TRL 4 and above. That policy setting explains the project's funding route, without establishing that any particular candidate will meet its development target.
Other project agreements reported by Dalimss News include support for BigEndian's AI vision chip programme and Agnikul's reusable rocket work. Each involves its own technology and development plan. Their inclusion in the same financing scheme does not make their technical progress comparable with a pharmaceutical research programme.
For this project, the next substantive evidence will concern the stated scientific work: completion of preclinical studies and the requirements for moving individual candidates towards trials. A three-year programme period should not be interpreted as a promised date for a commercial medicine. Different candidates also need to be assessed on their own results.
The public announcement does not give interest or conversion terms for the debt, identify a launch date for any treatment or present results from human trials. It establishes the signed support agreement and the work that Peptris proposes to undertake. Any later claim of clinical success will need its own supporting evidence and relevant regulatory status.
